Condition: Castration-Resistant Prostate Carcinoma · Metastatic Malignant Neoplasm in the Bone · Metastatic Prostate Carcinoma · Sponsor: University of Washington
This study investigates how well radium-223 works in treating patients with castration-resistant prostate cancer than has spread to the bones (bone metastases). Prostate cancer is the most common cancer in men and the second leading cause of cancer death. Furthermore, many men with notably advanced disease have been found to have abnormalities in DNA repair. The purpose of this research is to study the role of a DNA repair pathway in prostate cancer, specifically in response to administration of radium-223, an FDA-approved drug known to cause DNA damage to cancerous cells. Understanding how defects in the DNA repair pathway affects radium-223 treatment of prostate, may help doctors help plan effective treatment in future patients.
This description comes directly from the study's public registry record.
Jane Romani · 206-606-1909 · jromani@fredhutch.org
Always discuss trial participation with your own doctor first.
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Bozeman Health Deaconess Hospital | Bozeman, Montana, United States | Active Not Recruiting |
| Fred Hutch/University of Washington Cancer Consortium | Seattle, Washington, United States | Recruiting |
| University of Wisconsin-Madison | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04489719